Moreover, although beyond the capacity of the present study, future studies are warranted to illustrate the anticancer effects by combining VEGFR2 inhibitor and chemotherapy in glioma cells and to validate our findings in vivo using a xenograft experimental setup. The gene discussed is KDR; the disease is central nervous system cancer.